Press releases

Clinical presentations to include 12-month outcomes data from EVOLVE trial and results of the REPRISE I trial.

Advanced pacemaker platform designed to treat chronotropic incompetence, which affects up to 42 percent of pacemaker patients.

Clinical presentations will provide new insights for physicians who treat patients with heart disorders including sudden cardiac arrest, atrial fibrillation and heart failure.

Next-generation balloon catheter offers enhanced deliverability and expanded options for treating coronary artery lesions.

REPRISE I Trial Results to be Presented at EuroPCR 2012

Fesults “demonstrate continued progress towards improving our future growth profile and in executing our strategic plan," said CEO Hank Kucheman.

Device is intended for use in a wide range of electrophysiology (EP) procedures to facilitate the introduction and placement of diagnostic and therapeutic catheters within the heart.

Boston Scientific will webcast its conference call with financial results and business highlights for Q1 2012 on April 19. Learn how to tune in or watch the replay.

Advanced devices designed to treat chronotropic incompetence, which affects up to 42 percent of pacemaker patients.

BackStop Gel is a water-soluble polymer that urologists inject into the ureter to form a plug behind the stone, preventing migration of stone fragments of all sizes.

CTAF report supports safety, efficacy and positive health outcomes of bronchial thermoplasty for treatment of patients with severe asthma.

HORIZONS II AMI trial to enroll up to 10,000 patients worldwide, making it the largest randomized trial to study coronary stents in heart attack patients.

Results were presented at the American College of Cardiology Annual Scientific Sessions.

Quantitative Coronary Angiographic outcomes from PERSEUS and PLATINUM clinical trials presented at ACC 2012.

Company's WallFlex Biliary Stents now available with a Transhepatic delivery system for use by interventional radiologists in treating obstructions within the biliary tract.

Data to include two-year results from the PLATINUM Workhorse clinical trial, with follow-up data on PROMUS Element™ Everolimus-Eluting Platinum Chromium Stent.

Priority Health and HealthPartners issue new medical policies to cover catheter-based procedure shown to provide long-lasting control of severe asthma.

Radiofrequency ablation catheter designed to treat a variety of arrhythmias.

Company gains first and only commercially available subcutaneous ICD technology to offer lifesaving therapy to patients at risk of sudden cardiac arrest.

Five-year contract extends the existing commercial agreement, promotes continued investments in laser and fiber product development for urologic applications.

Next-generation coronary stent employs innovative alloy designed to improve acute performance.

TELIGEN family of ICDs, designed to treat sudden cardiac death, are the smallest and thinnest high-energy devices available in China.

ION™ and TAXUS® Liberte® Paclitaxel-Eluting Stent Systems now approved for treating patients with acute myocardial infarction in the U.S.

Moody's Investors Service has upgraded the Company's corporate credit rating to an investment grade rating, Baa3, with a stable outlook.

TruePath™ CTO Device designed to facilitate crossing of chronic total occlusions.

Studies published in peer-reviewed medical journals

New device offers excellent flexibility and large size for acquiring tissue samples.

“We continue to make progress with new product introductions, cost-saving initiatives and a strengthened presence in emerging markets," said CEO Hank Kucheman.

Platinum chromium coronary stent with enhanced delivery system now available in Europe and other international countries.

NICE report supports safety and effectiveness of Alair® System

Johnson and Johnson's patents found invalid

Boston Scientific will webcast its conference call with financial results for Q4 and full year ended December 31, 2011. Learn how to tune in or watch the replay.

Nine-month data presented at ISET support safety and efficacy of Epic Stent in iliac stenting

CMS pass-through payment and new CPT®[1] codes established for catheter-based procedure to treat severe asthma.

Boston Scientific's third new peripheral balloon catheter introduced in 2011 strengthens Company's position as a global leader in peripheral angioplasty balloons.

Boston Scientific Corporation (NYSE: BSX) announces U.S. Food and Drug Administration (FDA) approval of the Infinion™ 16 Percutaneous...

Extended ICD/CRT-D program offers warranties up to 10 years

New family of cardiac devices offers excellent longevity and industry's longest warranty.

Approval marks transition to internally manufactured everolimus-eluting stent in the U.S.

Innovative left atrial appendage closure device offers proven alternative to anticoagulant drugs for patients in atrial fibrillation at high risk for stroke.

Positive results from COBRA trial presented at TCT

EVOLVE trial evaluates fourth-generation everolimus-eluting coronary stent with ultra-thin abluminal bioabsorbable polymer.

Carotid WALLSTENT shown to be a safe alternative to carotid endarterectomy (CEA) in patients with carotid artery stenosis who are at increased risk for surgery.

PLATINUM Long Lesion clinical results presented at TCT show no cardiac death, heart attack or stent thrombosis at one year.

Long-term results presented from two studies evaluating advanced paclitaxel-eluting stent.

Multi-center study published in Gastrointestinal Endoscopy is largest ever reported on peroral cholangioscopy.

Clinical presentations to include 12-month data on fourth-generation SYNERGY™ Stent.

Video demonstration of CardioTeach™ app by Dr. Kenneth Stein available online

“Boston Scientific’s POWER strategy is the right top priority for the entire leadership team," said CEO Hank Kucheman.

BWallFlex study includes patients with bile duct strictures associated with post liver transplant anastomosis, prior abdominal surgery and chronic pancreatitis.

Company's everolimus-eluting platinum chromium stent now being marketed in world's second-largest DES market.

Boston Scientific will webcast its conference call with financial results and business highlights for Q3 2011 on Thursday, October 20. Learn how to tune in.

Third-generation bare-metal stent designed to offer improved acute performance in treating patients with coronary artery disease

Study designed to assess preliminary safety and efficacy of chronic vagal nerve stimulation in heart failure patients

U.S. Court of Appeals for the Federal Circuit found in favor of the Company in a 1998 patent infringement suit involving Johnson & Johnson

Ultra-low profile, highly deliverable balloon dilatation catheter offers physicians exceptional performance in peripheral angioplasty procedures.

Company supports women's health through online community launched by American Urogynecologic Society (AUGS) at annual meeting.

Mahoney Has Served as Worldwide Chairman, Medical Device and Diagnostics Group, Johnson & Johnson

Boston Scientific Corporation (NYSE: BSX) today issued the following statement from John Pedersen, Senior Vice President and President of the Company's...

Company also introduces industry's first iPhone®/iPad® app for healthcare professionals using SCS

Company's fully covered metal stent now approved in Canada for use in treating benign biliary strictures

U.S. Court of Appeals for the First Circuit has affirmed the dismissal of a securities fraud case in connection with the 2004 recall of the TAXUS® Express2 Paclitaxel-Eluting Coronary Stent System

Investment supported by grant funding from Government through IDA Ireland

Company also announces new share repurchase, China investment and restructuring program

"This repurchase program reflects our confidence in the strength of the Company's long-term business prospects, earnings growth potential and our ability to generate strong cash flow," said Ray Elliott, President and CEO

Investment to support development of local manufacturing capabilities and training center

Fitch Ratings upgrades Company's corporate credit rating to an investment grade rating, BBB-, with a stable outlook

Boston Scientific will webcast its conference call with financial results and business highlights for Q2 2011 on Thursday, July 28. Learn how to tune in.

European ASTI study to evaluate new nitinol stent to treat carotid artery disease

Recently-launched PTA catheter, designed for a wide range of peripheral angioplasty procedures, expected to be site’s biggest launch this year

Expanded Heredia plant to manufacture a broad line of medical devices

Comprehensive identifies pain as a major US health problem and lays the foundation for chronic pain care, research and education for the next decade.

System had earlier received FDA clearance and CE Mark approval for obstructing or reducing blood flow in the peripheral vasculature during embolization procedures.

Bipartisan bill is intended to modernize the U.S. patent system

Low-profile, high-pressure balloon offers physicians exceptional performance in a single platform for peripheral angioplasty procedures

Patents relate to coatings (drug and polymer) for drug-eluting stents

Action affects products distributed in U.S. and its territories; Atlantis® SR Pro available immediately as a substitute

Boston Scientific becomes the first and only company to offer two distinct drug-eluting stents to treat small vessels

New technology designed to improve lead anchoring for physicians to be introduced at INS World Congress

12-month clinical data demonstrate low adverse event rates for Boston Scientific's 2.25 mm PROMUS Element Platinum Chromium Stent

Results for Boston Scientific WATCHMAN device presented at EuroPCR

Five-year data from RISA Trial presented at ATS adds to clinical evidence showing long-term safety of Boston Scientific's Alair® Bronchial Thermoplasty System

Jury in the District of Delaware found that Cordis owed Boston Scientific approximately $19.5 million for infringing its Jang patent.

Patients receive first device-based treatment for severe asthma

Elliott to remain on Board as non-executive director.

Company sponsors additional efforts to promote education and awareness of severe asthma

Innovative Fine Needle Aspiration technology expands diagnostic capabilities in pancreas and gastrointestinal tract

World's smallest and thinnest high-energy CRT-Ds and ICDs offer new features to optimize patient management

ALTITUDE analyzes outcomes data from patients monitored by the LATITUDE® Patient Management system.

Implanting U.S. centers can qualify for a full refund if they have to replace a COGNIS® CRT-D device due to unmanageable PNS within six months post-implant.

System used in 25,000 patient procedures at 600 facilities worldwide since 2007

Radiofrequency ablation catheter designed to treat a variety of arrhythmias

The scheduled clinical presentations will provide new insights for physicians who treat patients with heart disorders including sudden cardiac arrest, atrial fibrillation and heart failure.

Innovative alloy designed to improve new coronary stent's acute performance

“We had several notable accomplishments during the quarter that illustrate progress toward strategic milestones,” said Ray Elliott, Company President and CEO.

Company will webcast its conference call with financial results and business highlights for Q1 2011 on April 21. Learn how to tune in.

Study will evaluate safety and effectiveness in patients with stenosis of the superficial femoral artery (SFA) or proximal popliteal artery (PPA).

Reduction of geographic miss and bail-out stenting observed with highly visible PROMUS Element Stent

Lower event rates for new alloy and stent design versus older drug-eluting stent model

Clinical presentations to include 12-month data on PROMUS Element™ Platinum Chromium Stent